Übersetzung für "Visceral leishmaniasis" in Deutsch

As a Bangladeshi researcher at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), I have been intimately involved in local efforts to eradicate visceral leishmaniasis (VL, also known as kala-azar), one of the diseases covered by the London Declaration.

Falsified versions of generic miltefosine capsules for the treatment of visceral leishmaniasis (black fever), a fatal parasitic disease, were administered to hundreds of patients in Bangladesh in 2008.

Since its foundation, DNDi has made available six treatments for neglected diseases, including two for malaria, one for sleeping sickness, one for visceral leishmaniasis (VL) in East Africa, a set of treatments for VL in Asia, and a paediatric dosage form of benznidazole for Chagas disease.

Without treatment, some of these diseases, notably sleeping sickness and visceral leishmaniasis, are fatal.

Active agents containing an effective amidine function or guanidine function may be used inter alia for inhibiting blood coagulation, for the prophylaxis and therapy of visceral and cutaneous leishmaniasis, trypanosomiasis (African sleeping sickness), pneumonia caused by pneumocystis carinii (PCP), for inhibiting the growth of malign tumors, blood pressure reduction, neuroprotection, and for combating viral infections such as influenza and HIV infections.

While serious tissue destructions occur with mucocutan and cutan leishmaniasis, an untreated visceral leishmaniasis (Kala-Azar), in most cases, has fatal results.

The project aims to test new treatments for visceral leishmaniasis (VL or kala-azar) in East Africa and co-infection of the disease with HIV in Ethiopia.

Recent epidemiological evaluations by WHO resulted in an estimate of around one million cases and up to 30,000 deaths caused by visceral leishmaniasis annually.

These efforts have led to the implementation of six improved treatments to answer urgent needs of patients with malaria, sleeping sickness, visceral leishmaniasis, and Chagas disease.

Visceral leishmaniasis, also referred to as kala-azar, Dumdum fever, and black fever, is caused by protozoan parasites and is characterized by symptoms of sudden weight loss, irregular fever, nodular rash, anemia, and inflammation of the liver and spleen.

We support efforts to create a new generation of more effective and less toxic drugs to treat malaria, TB, visceral leishmaniasis (black fever), human African trypanosomiasis (sleeping sickness), onchocerciasis (river blindness), and lymphatic filariasis (elephantiasis), and to control severe diarrhea.

There are several major clinical types of this infection including cutaneous, diffuse cutaneous, mucocutaneous and visceral leishmaniasis.

The other high-opportunity diseases we target are visceral leishmaniasis (black fever), soil-transmitted helminthiases (hookworm, roundworm, and whipworm), schistosomiasis, dracunculiasis (guinea worm), and human African trypanosomiasis (known as HAT or sleeping sickness).

And somebody like Dr. Victoria Hale, who started the world's first nonprofit pharmaceutical company, and whose first drug will be fighting visceral leishmaniasis, also known as black fever.